The Benefits of Early Detection: Evidence From Modern International Mammography Service Screening Programs

Abstract

Research from randomized controlled trials initiated up to 60 years ago consistently confirms that regular screening with mammography significantly reduces breast cancer mortality. Despite this success, there is ongoing debate regarding the efficacy of screening, which is confounded by technologic advances and concerns about cost, overdiagnosis, overtreatment, and equitable care of diverse patient populations. More recent screening research, designed to quell the debates, derives data from variable study designs, each with unique strengths and weaknesses. This article reviews observational population-based screening research that has followed the early initial long-term randomized controlled trials that are no longer practical or ethical to perform. The advantages and disadvantages of observational data and study design are outlined, including the three subtypes of population-based observational studies: cohort/case-control, trend, and incidence-based mortality/staging. The most recent research, typically performed in countries that administer screening mammography to women through centralized health service programs and directly track patient-specific outcomes and detection data, is summarized. These data are essential to understand and inform construction of effective new databases that facilitate continuous assessment of optimal screening techniques in the current era of rapidly developing medical technology, combined with a focus on health care that is both personal and equitable.

Early Detection Program for Breast and Cervical Cancer in Indonesia: How is Implementation?

“…Eby's research in 2022 also stated that the results of observational studies conducted in Europe, Canada, Australia, New Zealand, and Korea showed that the implementation of early breast cancer detection programs significantly reduced the morbidity of advanced-stage cancer and reduced the need for chemotherapy. Moreover, radiation therapy extends patients' lives, reducing the risk of breast cancer death (Eby et al, 2022).…”